重组人干扰素α2b对喘息性支气管炎患儿炎性因子、免疫功能的影响

Effect of Recombinant Human Interferon α2b on Inflammatory Factors and Immune Function in Children with Asthmatic Bronchitis

目的:分析重组人干扰素α2b对喘息性支气管炎患儿炎性因子、免疫功能的影响。方法:选取2018年1月-2019年4月笔者所在医院喘息性支气管炎患儿74例,按治疗方案分为研究组(n=37)与对照组(n=37),对照组予以异丙托溴铵及吸入用糖皮质激素,研究组予以重组人干扰素α2b联合异丙托溴铵及吸入用糖皮质激素。对比两组疗效、临床症状消失时间(发热、喘息、咳嗽、肺部啰音)、治疗前后T淋巴细胞亚群(CD4+、CD8+)水平及血清炎性因子[白三烯E4(LTE4)、嗜酸性粒细胞阳离子蛋白(ECP)]水平。结果:研究组总有效率为97.30%(36/37),高于对照组的83.78%(31/37),差异有统计学意义(P<0.05);研究组发热、喘息、咳嗽、肺部啰音消失时间均早于对照组,差异均有统计学意义(P<0.05);治疗后研究组CD4+水平高于对照组,CD8+水平低于对照组,差异有统计学意义(P<0.05);治疗后,研究组血清LTE4、ECP水平均低于对照组,差异均有统计学意义(P<0.05)。结论:重组人干扰素α2b联合异丙托溴铵及吸入用糖皮质激素治疗喘息性支气管炎患儿效果显著,能改善免疫功能,下调血清LTE4、ECP水平,抑制炎症反应,改善患儿临床症状。

Objective:To analyze the effect of Recombinant Human Interferon α2b on inflammatory factors and immune function in children with asthmatic bronchitis.Method:A total of 74 children with asthmatic bronchitis in our hospital from January 2018 to April 2019 were selected and divided into the study group (n=37) and the control group (n=37) according to the treatment schemes.The control group was given Ipratropium Bromide and Inhaled Glucocorticoids,and the study group was given Recombinant Human Interferon α2b combined with Ipratropium Bromide and Inhaled Glucocorticoid.The efficacy,the time of disappearance of clinical symptoms (fever,wheezing,cough,pulmonary rales),T lymphocyte subsets (CD4+,CD8+) levels,serum inflammatory factor [leukotriene E4 (LTE4),eosinophilic cationic protein (ECP)] levels before and after treatment of the two groups were compared.Result:The total effective rate of the study group was 97.30% (36/37),which was higher than 83.78% (31/37) of the control group,and the difference was statistically significant (P<0.05).The time of disappearance of fever,wheezing,cough and pulmonary rales in the study group were earlier than those of the control group,and the differences were statistically significant (P<0.05).After treatment,the level of CD4+ in the study group was higher than that of the control group,and the level of CD8+ was lower than that of the control group,and the differences were statistically significant (P<0.05).After treatment,the levels of serum LTE4 and ECP in the study group were lower than those of the control group,and the differences were statistically significant (P<0.05).Conclusion:The effect of Recombinant Human Interferon α2b combined with Ipratropium Bromide and Inhaled Glucocorticoids on children with asthmatic bronchitis is significant,it can improve the immune function,reduce serum LTE4 and ECP levels,inhibit inflammation response and improve clinical symptoms of children.